ArticleAmerican journal of translational research2023
Expression and clinical significance of tumor necrosis factor receptor-associated factor 1 in peripheral blood of patients with advanced lung cancer.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Pan-cancer analysis of the TRAF family genes and their correlation with prognosis, TME, immune and drug sensitivity.European journal of medical research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo assess the serum level of tumor necrosis factor receptor related factor 1 (TRAF1) in advanced lung cancer patients and its clinical significance.
methodsIn this retrospective study, the serum level of TRAF1 in 50 patients with stage III-IV lung cancer and 50 healthy people who received physical examination during the same period were detected and compared. The differences in serum TRAF1 level in patients with lung cancer in terms of gender, age, smoking status, pathological type, tumor location, TNM stage and other clinicopathological features were analyzed. The 50 patients with lung cancer were treated with conventional chemotherapy for 2 cycles, and serum TRAF1 level was tested. The area under the curve (AUC) was calculated to evaluate the diagnostic value of serum TRAF1 for advanced lung cancer.
resultsThe serum level of TRAF1 in lung cancer patients was significantly higher than that of healthy controls (P < 0.05). The serum level of TRAF1 in patients with stage IV lung cancer was significantly higher than that in patients with stage III lung cancer (P < 0.05). Serum level of TRAF1 in lung adenocarcinoma and lung squamous cell carcinoma group after chemotherapy was significantly lower than that before chemotherapy (P < 0.05); However, the serum level of TRAF1 in small cell lung cancer group after chemotherapy had no significant change compared with that before chemotherapy (P > 0.05). The AUC of serum TRAF1 for the diagnosis of lung cancer was 0.903, and the yoden index was 0.668. The best cut-off value of serum TRAF1 for the diagnosis of lung cancer was 113.87 pg/ml, with a sensitivity of 90.6% and a specificity of 78.57%.
conclusionSerum level of TRAF1 has potential diagnostic value for advanced lung cancer. TRAF1 could assist clinicians to diagnose lung cancer patient and assess patient's condition.
Indexed as
Identifiers
37056842PMC10086928W4365483083What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.